Showing 6941-6950 of 9462 results for "".
- Medicine X Launches Eczema Xplained Patient Story To Drive Understanding and Awareness of ADhttps://practicaldermatology.com/news/medicine-x-launches-eczema-xplained-patient-story-to-drive-understanding-and-awareness-of-ad/2460519/Medicine X today is launching Eczema Xplained, its first illustrated story in the U.S. on atopic dermatitis, the most comm
- Arena Pharmaceuticals Announces First Subject Dosed in Phase 2 Trial Evaluating Etrasimod in Alopecia Areatahttps://practicaldermatology.com/news/arena-pharmaceuticals-announces-first-subject-dosed-in-phase-2-trial-evaluating-etrasimod-in-alopecia-areata/2460515/The first subject has been dosed in
- New York’s Mount Sinai Health System Names New Chair of Dermatology and New Dean For Clinical Therapeuticshttps://practicaldermatology.com/news/new-yorks-mount-sinai-health-system-names-new-chair-of-dermatology-and-new-dean-for-clinical-therapeutics/2460486/Emma Guttman-Yassky, MD, PhD, is the new Chair of the Kimberly and Eric J. Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai and the Mount Sinai Health System. She will be the first woman to serve as Chair of a Department of Dermatology in New York City. S
- And the Winner Is...Dr. Junko Takeshita of University of Pennsylvania Wins 2020 Childhood Eczema Challenge Granthttps://practicaldermatology.com/news/and-the-winner-isdr-junko-takeshita-of-university-of-pennsylvania-wins-2020-childhood-eczema-challenge-grant/2460481/The
- Arena Completes Full Enrollment of Etrasimod Phase 2 ADVISE Trial for ADhttps://practicaldermatology.com/news/arena-completes-full-enrollment-of-etrasimod-phase-2-advise-trial-for-ad/2460403/
- FDA Approves Ortho Dermatologics' Jublia to Treat Onychomycosis in Patients As Young As Six Years Oldhttps://practicaldermatology.com/news/fda-approves-ortho-dermatologics-jublia-to-treat-onychomycosis-in-patients-as-young-as-six-years-old/2460371/Bausch Health Companies Inc. and its dermatology business, Ortho Dermatologics received FDA approval for a supplemental New Drug Application (sNDA) for Jublia (efinaconazole) topical solution, 10%, a treatment for onychomycosis, a fungal infection of the toenails, which extends the age range incl
- LEO Pharma Enters License Agreement with Oneness Biotech, Microbio Shanghai for Atopic Dermatitis and Asthma Drug Candidatehttps://practicaldermatology.com/news/leo-pharma-enters-license-agreement-with-oneness-biotech-microbio-shanghai-for-atopic-dermatitis-and-asthma-drug-candidate/2460353/
- Industry Responds to COVID-19: Henry Schein Medical, PCA Skinhttps://practicaldermatology.com/news/industry-responds-to-covid-19-henry-schein-medical-pca-skin/2460344/Henry Schein Medical. Henry Schein Medical is making
- Neauvia’s Introduces Zaffiro, A Two-Part Solution to Skin Rejuvenationhttps://practicaldermatology.com/news/neuvias-introduces-zaffiro-a-two-part-solution-to-skin-rejuvenation/2460305/Neauvia introduced Zaffiro to the media at an event held in New York City’s Hudson Yards, featuring New York City dermatologist Amy Lewis, MD Launched in the US in late 2019, the Zaffiro device is a dual facial rejuve
- NEA/PeDRA Offer New Childhood Eczema Challenge Granthttps://practicaldermatology.com/news/neapedra-offer-new-childhood-eczema-challenge-grant/2460298/The